Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Transcode Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 5
- −6 vs. Q1 2023
- Shares held
- 207.3K
- −54.9K (−21.0%) vs. Q1 2023
- Total value
- $476.6K
- +$388.0K (+437.7%) vs. Q1 2023
- New holders
- 3
- 0 more added
- Sold out
- 9
- 2 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 188,437 | $433.4K | 1.49% | +188,437 | New |
| Susquehanna International Group, LLP | 13,662 | $31.4K | 0.00% | +13,662 | New |
| Tower Research Capital LLC (TRC) | 5,108 | $11.7K | 0.00% | −1,243−19.6% | Reduced |
| Wells Fargo & Company | 4 | $9 | 0.00% | −47−92.2% | Reduced |
| Royal Bank of Canada | 45 | $0 | 0.00% | +45 | New |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −75,683−100.0% | Sold out |
| Sheets Smith Wealth Management | 0 | $0 | 0.00% | −60,000−100.0% | Sold out |
| One68 Global Capital, LLC | 0 | $0 | 0.00% | −30,120−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −21,019−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −19,407−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −15,060−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,122−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −1,385−100.0% | Sold out |